Eli Lilly's Strategic Investment in Boston Seaport
Eli Lilly, a global pharmaceutical leader, has made a significant investment in biotechnology innovation by opening a new $700 million Research and Development (R&D) center in the Boston Seaport. This move strengthens Lilly's capabilities in RNA and DNA research and marks the expansion of its biotech-hosting Gateway Labs to the East Coast for the first time.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
